Clinical Research Directory

A Study of Zasocitinib in Adults With Nonsegmental Vitiligo

Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin color (melanin). This leads to the formation of patches of skin with less or no pigment (depigmentation). These patches can occur anywhere on the body. In the nonsegmental form of vitiligo, similar patches occur on both sides of the body (symmetrical patches). The main aim of this study is to learn how safe zasocitinib is, how well it works and how well it is tolerated by adults with nonsegmental vitiligo. The participants will receive the study treatment (either zasocitinib or placebo) for up to 1 year (52 weeks). The placebo looks like the zasocitinib capsule but does not have any medicine in it. Participants who receive placebo at the beginning will change to zasocitinib after about 6 months. During the study, participants will visit their study clinic 11 times.

Topical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized Vitiligo

This randomized comparative study will evaluate the efficacy and safety of topical ruxolitinib 1.5% cream compared with topical tacrolimus 0.1% ointment, each combined with 308-nm excimer laser therapy, in patients aged 12 years or older with stable localized non-segmental facial vitiligo. Forty participants will be randomly assigned in a 1:1 ratio to receive one of the topical treatments twice daily for 24 weeks plus excimer laser treatment. Clinical, dermoscopic, patient-reported, and histopathological outcomes will be assessed before and after treatment, with follow-up for recurrence.